Background

Ultra-sensitive and selective detection and traceable quantification of DNA interaction with metallo-drugs used for cancer therapy can be used to increase drug selectivity and minimise side-effects. The development of primary analytical methods such as species-specific and post-column isotope dilution mass spectrometry (IDMS) for the accurate quantification of Pt drug adduct formation, will enable, for the first time, quality control of existing MS assays intended for clinical use...